We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Eden Biodesign and Borean Pharma Sign Deal to Develop Therapeutic Candidate for the Treatment of Cancer
News

Eden Biodesign and Borean Pharma Sign Deal to Develop Therapeutic Candidate for the Treatment of Cancer

Eden Biodesign and Borean Pharma Sign Deal to Develop Therapeutic Candidate for the Treatment of Cancer
News

Eden Biodesign and Borean Pharma Sign Deal to Develop Therapeutic Candidate for the Treatment of Cancer

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Eden Biodesign and Borean Pharma Sign Deal to Develop Therapeutic Candidate for the Treatment of Cancer"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Eden Biodesign Ltd and Borean Pharma ApS announced that they have signed an agreement under which Eden will manufacture MBP-DC-SIGN, a therapeutic candidate for the treatment of a range of cancers, for Borean to use in key preclinical studies. The project is expected to complete early in 2008.

MBP-DC-SIGN is one of Borean’s products to be based on the Mannose-Binding protein (MBP) platform. The MBP platform is delivering a series of highly potent therapeutics for the treatment of cancers, and is the only scaffold that can induce complement-induced lysis.

“Working with Eden Biodesign will allow us to rapidly progress the development of this promising drug candidate” commented Dr Johanna Holldack, CEO of Borean Pharma ApS. “We are delighted to have this project conducted at Eden Biodesign’s state of the art facility in Liverpool.”

“Our facilities are designed to rapidly produce high quality biopharmaceuticals and we’re really pleased to have been selected by Borean Pharma ApS, based on our experience and expertise which will assist them in the acceleration of the development of the MBP-DC-SIGN” added Dr Crawford Brown, CEO of Eden Biodesign.

The agreement with Borean Pharma is the fourth contract to be announced by Eden Biodesign in the past 7 weeks, following announcements for cGMP manufacturing and development projects with CRUK, University of Birmingham and UMIP.

Advertisement